Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
Johanna C. Bendell(Dana-Farber Cancer Institute), S.‐H.I. Ou(Chongqing University of Posts and Telecommunications), Julie R. Brahmer(Johns Hopkins University), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Richa Dua(Revolution Medicines (United States)), Alexander I. Spira(Virginia Cancer Specialists), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Jorge H. Limón-Pacheco(University of Colorado Denver), Misako Nagasaka(University of California, Irvine), Suramanyam Chittivelu(Revolution Medicines (United States)), Michael S. Gordon(Pinnacle Oncology Hematology), Kimmie Ng(Dana-Farber Cancer Institute), S. Gail Eckhardt(Bayer (United States)), Jonathan W. Riess(University of California Davis Medical Center), Z. Wang(Revolution Medicines (United States)), Conor Steuer(Emory University), Anna Capasso(The University of Texas at Austin), X. Wang(Revolution Medicines (United States)), M. Koczywas(City Of Hope National Medical Center), Serena Masciari(AVEO Oncology (United States))
Cited by 27
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k